BlackRock, Inc. Reduces Stake in LifeCore Biomedical, Inc.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a reduction in its ownership stake in LifeCore Biomedical, Inc. As of September 30, 2025, BlackRock owns 1,834,319 shares, representing 4.9% of the outstanding common stock. This marks a decrease of 40,507 shares from its previous filing, with the value of the holdings dropping by $3,318,856.69, a 21.8% decrease. The filing indicates that BlackRock holds sole voting power over 1,804,675 shares and sole dispositive power over all 1,834,319 shares. The filing also certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.